Skip to main content

Find Clinical Trials

Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,057 public trials 2,038 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas

NCT01280526

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Hôpital Henri Mondor Créteil, France

CHU de Dijon Dijon, France

Hôpital Claude Huriez Lille, France

Centre Léon Bérard Lyon, France

View Trial Details

Completed

Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00184080

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations: USC/Norris Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Completed

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

NCT00098670

Conditions: B-cell Chronic Lymphocytic Leukemia, Chronic Disease, Disease Attributes, +18 more
Locations: Cancer and Leukemia Group B Chicago, Illinois, United States

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States

View Trial Details

Completed

Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

NCT00121199

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: SWOG Portland, Oregon, United States

View Trial Details

Completed

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

NCT01358253

Conditions: Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations: Ruijin Hospital Shanghai, Shanghai Municipality, China

View Trial Details

Completed

A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma

NCT00872521

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Adelaide, Australia

Box Hill, Australia

Brisbane, Australia

Camperdown, Australia

View all 16 locations

View Trial Details

Completed

Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants

NCT00606437

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +21 more
Locations: Duke University Health System Durham, North Carolina, United States

View Trial Details

Completed

Infectious Causes of Uveitis

NCT00676624

Conditions: Eye Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations: Glostrup Hospital Glostrup Municipality, Denmark

View Trial Details

Completed

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

NCT00392496

Conditions: Adult Diffuse Large Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations: National Cancer Institute of Canada Clinical Trials Group Kingston, Ontario, Canada

View Trial Details

Completed

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

NCT00402181

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Duarte, California, United States

Norwalk, Connecticut, United States

Indianapolis, Indiana, United States

Rochester, Minnesota, United States

View all 13 locations

View Trial Details